Loading... please wait

On the Precipice of Change: Paradigm Shifts in Psychedelic Assisted Therapy (PAT) and the Future of Mental Health


Rick Doblin, President, Multidisciplinary Association for Psychedelic Studies (MAPS)
Isaac Gilmore, Deputy Veteran Affairs Officer, TREAT California; Advisor, Concordia
Loree Sutton, Former New York City Commissioner of Veterans Affairs
Brett Waters, Co-Founder & Executive Director, Reason for Hope


With lead Programming partner

TREAT - On the Precipice of Change: Paradigm Shifts in Psychedelic Assisted Therapy (PAT) and the Future of Mental Health

“Psychedelics can help people move beyond their understanding of who they are and broaden it.”     

– Rick Doblin

“The FDA views these as shown as safe through clinical trials and potentially much more effective than current treatments we have.”

– Brett Waters

“Something our country desperately needs is more connective tissue between our veteran community and our community at large.”

– Isaac Gilmore

“You haven’t seen complex PTSD until you’ve seen it in a veteran […] Treatment as usual is not the answer.”

– Loree Sutton

Key takeaways & next steps:

  • There is growing attention to psychedelics and their role in transforming mental health. Much progress has been made in researching and advocating for the therapeutic use of psychedelics, particularly MDMA.
  • Psychedelic therapy involves a deep dive into the causes of trauma, emphasizing that patients become their own healers. The therapy focuses on integration and the brain’s plasticity to facilitate long-lasting healing. It’s important to train the next generation to continue the movement for psychedelic therapy and mental health transformation.
  • Access to psychedelic-assisted therapy, not limited to MDMA but also including substances like ketamine, psilocybin, ibogaine, and ayahuasca, should be globalized.
  • TREAT California is a state agency initiative aiming to raise $5 billion for large-scale clinical trials, research, and access to psychedelic therapy. The initiative seeks to collaborate with the NIH, FDA, and DEA and potentially serve as a model for other states.
  • There is a need for bipartisan support in advancing policies that enable access to psychedelic therapies and the implementation of pragmatic measures to reduce research barriers.
  • Veterans lead the charge in advocating for psychedelic therapies, driven by their personal experiences and the proven efficacy of these treatments in addressing complex PTSD and military-related trauma.